GSK (GSK) president acquires ADS through dividend reinvestment

Rhea-AI Filing Summary

GSK plc reports that executive Maya Martinez-Davis acquired 70.566 American Depositary Shares at $59.5200 each on 2026-02-20 through dividend reinvestment in her GSK Executive Supplemental Savings Plan account. The transaction took place on the New York Stock Exchange and was disclosed as an initial notification.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of notional ADS within Ms Martinez-Davis's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$59.5200	70.566
			d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-02-20
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: February 27, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider transaction did GSK (GSK) report for Maya Martinez-Davis?

GSK reported that executive Maya Martinez-Davis acquired 70.566 American Depositary Shares. The ADS were credited to her GSK Executive Supplemental Savings Plan account through dividend reinvestment at a price of $59.5200 per ADS on February 20, 2026, on the New York Stock Exchange.

How were the GSK (GSK) ADS acquired by Maya Martinez-Davis?

The ADS were acquired through reinvestment of dividends in a savings plan, not an open-market purchase. Dividends paid on her holdings were used to buy 70.566 American Depositary Shares at $59.5200 each within the GSK Executive Supplemental Savings Plan account.

What type of security did GSK (GSK) disclose in this insider transaction?

The transaction involved American Depositary Shares, or ADS, representing GSK equity listed in the United States. These ADS, identified by ISIN US37733W2044, were credited to Maya Martinez-Davis’s plan account following dividend reinvestment, rather than a direct cash purchase on the open market.

On what date and exchange did the GSK (GSK) executive’s ADS transaction occur?

The transaction occurred on February 20, 2026, and was executed on the New York Stock Exchange. The filing specifies the venue as XNYS, confirming the ADS trade location for the dividend reinvestment credited to the GSK Executive Supplemental Savings Plan account.

Was the GSK (GSK) insider dealing filing an initial notification or an amendment?

The disclosure is identified as an initial notification, not an amendment. This means it is the first formal reporting of Maya Martinez-Davis’s February 20, 2026 acquisition of 70.566 GSK American Depositary Shares via dividend reinvestment in her executive savings plan account.

Who is the person subject to the GSK (GSK) transaction notification?

The person is Maya Martinez-Davis, described as a President at GSK. She qualifies as a person discharging managerial responsibilities, which requires public disclosure of her acquisition of GSK American Depositary Shares through dividend reinvestment in the Executive Supplemental Savings Plan.